Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Dermatovenerology Department, Celje General and Teaching Hospital, Celje, Slovenia-EU, Institute of Anatomy, Histology and Embryology, Faculty of Medicine, University of Maribor, Maribor, Slovenia.
J Investig Med. 2021 Feb;69(2):393-396. doi: 10.1136/jim-2020-001390. Epub 2020 Oct 22.
Vitiligo, an autoimmune disease, is a depigmentation skin disorder characterized by hypopigmentation spots and patches that are difficult to treat. The purpose of this study is to analyze the clinical efficacy of simvastatin in the treatment of vitiligo. From December 2016 to October 2019, five vitiligo patients from Peking Union Medical College Hospital were treated with simvastatin and tacrolimus. For simvastatin, the first three patients (patient 1, patient 2, and patient 3) began to take 40 mg/day, and the latter two patients began to take 20 mg/day. From week 5, patients 1 and 2 received 20 mg simvastatin once a day. And the 0.1% tacrolimus ointment was used topically. The response was measured using the Vitiligo European Task Force (VETF) scoring system at baseline and at the fourth and eighth weeks of treatment. The results of the VETF score showed that three of the patients achieved significant clinical efficacy. There was no significant improvement in the other two cases. No serious acute or chronic side effects were observed. In conclusion, our results suggest that conventional oral simvastatin is safe, although it may not be effective in the treatment of vitiligo.
白癜风是一种自身免疫性疾病，是一种以色素脱失斑和斑块为特征的皮肤色素减退症，治疗困难。本研究旨在分析辛伐他汀治疗白癜风的临床疗效。2016 年 12 月至 2019 年 10 月，北京协和医院的 5 例白癜风患者接受了辛伐他汀和他克莫司治疗。对于辛伐他汀，前 3 例患者（患者 1、患者 2 和患者 3）开始每天服用 40mg，后 2 例患者开始每天服用 20mg。从第 5 周开始，患者 1 和 2 每天服用 20mg 辛伐他汀一次。并局部使用 0.1%他克莫司软膏。在基线和治疗的第 4 周和第 8 周，使用白癜风欧洲工作组（VETF）评分系统测量反应。VETF 评分的结果表明，3 名患者获得了显著的临床疗效。另外 2 例无明显改善。未观察到明显的急性或慢性不良反应。总之，我们的结果表明，常规口服辛伐他汀是安全的，尽管它可能对白癜风的治疗无效。
